GEMOXEL Regimen May Be Better Than Standard Therapy for Pancreatic Cancer

Share this content:
GEMOXEL Regimen May Be Better Than Standard Therapy for Pancreatic Cancer
GEMOXEL Regimen May Be Better Than Standard Therapy for Pancreatic Cancer
The GEMOXEL (gemcitabine, oxaliplatin, capecitabine) regimen may be safe and more efficient than standard therapy with gemcitabine alone in the treatment of patients with metastatic pancreatic cancer, a study published in the journalCancer Chemotherapy and Pharmacology has shown.
READ FULL ARTICLE From Oncology Nurse Advisor
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters